



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Veltuzumab

Cat. No.:	HY-P99224
CAS No.:	728917-18-8
Target:	Integrin
Pathway:	Cytoskeleton
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody. Veltuzumab has low EC ₅₀ value of 0.08-0.09 µg/mL in the Daudi cell line. Veltuzumab can be used for the research of cancer including non-Hodgkin lymphoma (NHL) ^[1] .								
IC₅₀ & Target	EC ₅₀ : 0.08-0.09 µg/mL (in the Daudi cell line) ^[1]								
In Vitro	<p>Veltuzumab significantly reduces off-rates in human lymphoma cell lines, as well as increases complement-dependent cytotoxicity in 1 of 3 cell lines, but no other in vitro differences^[1].</p> <p>Veltuzumab (0.001-10 µg/mL, 3 h) has low EC₅₀ value of 0.08-0.09 µg/mL in the Daudi cell line^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Cytotoxicity Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>4 lymphoma cell lines (SU-DHL-6, Daudi, Raji and WSU-FSCCL)</td> </tr> <tr> <td>Concentration:</td> <td>5 µg/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>4 days</td> </tr> <tr> <td>Result:</td> <td>Had the sensitivity correlated with CD20 expression (SU-DHL6> Raji > Daudi > WSU-FSCCL).</td> </tr> </table>	Cell Line:	4 lymphoma cell lines (SU-DHL-6, Daudi, Raji and WSU-FSCCL)	Concentration:	5 µg/mL	Incubation Time:	4 days	Result:	Had the sensitivity correlated with CD20 expression (SU-DHL6> Raji > Daudi > WSU-FSCCL).
Cell Line:	4 lymphoma cell lines (SU-DHL-6, Daudi, Raji and WSU-FSCCL)								
Concentration:	5 µg/mL								
Incubation Time:	4 days								
Result:	Had the sensitivity correlated with CD20 expression (SU-DHL6> Raji > Daudi > WSU-FSCCL).								
In Vivo	<p>Veltuzumab (i.v. or s.c.; 5, 20 and 60 µg; single) can control tumor growth or deplete circulating or sessile B cells at low doses in mouse models of intraperitoneal and subcutaneous doses^[1].</p> <p>Veltuzumab (i.p.; 0.05-35 µg) are significantly effective in vivo^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Lymphoma xenograft model^[1]</td> </tr> <tr> <td>Dosage:</td> <td>5, 20 and 60 µg</td> </tr> <tr> <td>Administration:</td> <td>intraperitoneal and subcutaneous, single</td> </tr> <tr> <td>Result:</td> <td>Showed low dose of 0.05 µg increased the MST.</td> </tr> </table>	Animal Model:	Lymphoma xenograft model ^[1]	Dosage:	5, 20 and 60 µg	Administration:	intraperitoneal and subcutaneous, single	Result:	Showed low dose of 0.05 µg increased the MST.
Animal Model:	Lymphoma xenograft model ^[1]								
Dosage:	5, 20 and 60 µg								
Administration:	intraperitoneal and subcutaneous, single								
Result:	Showed low dose of 0.05 µg increased the MST.								

Animal Model:	SCID mice ^[1]
Dosage:	0.5, 0.25, 0.1, or 0.05 µg; 35, 3.5, 0.35, or 0.035 µg
Administration:	intraperitoneal, single
Result:	Improved significantly survival.

REFERENCES

[1]. David M Goldenberg, et al. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA